"Designing Growth Strategies is in our DNA"

Plasma Fractionation Market Size, Share & COVID-19 Impact Analysis, By Product (Immunoglobulin, Albumin, Coagulation Factors, Protease Inhibitors, and Others), By Application (Immunology & Neurology, Hematology, Critical Care, Pulmonology, and Others), By End-user (Hospitals & Clinics, Clinical Research Laboratories, and Others), and Regional Forecast, 2021-2028

Region : Global | Format: PDF | Report ID: FBI101614



Play Audio Listen to Audio Version

The global plasma fractionation market size was USD 29.10 billion in 2020. The global impact of COVID-19 has been unprecedented and staggering, with plasma fractionation products witnessing a positive demand shock across all regions amid the pandemic. Based on our analysis, the global market exhibited a significant growth of 14.4% in 2020. The market is projected to grow from USD 32.45 billion in 2021 to USD 51.83 billion in 2028 at a CAGR of 6.9% in the 2021-2028 period. The sudden fall in CAGR is attributable to this market’s demand and growth, returning to pre-pandemic levels once the pandemic is over.

Plasma fractionation has always ignited curiosity among researchers and industrialists alike. The therapeutic efficacies of blood plasma to treat and manage immunodeficiency diseases have helped the growth of the market. Cryo precipitation and ethanol fractionation are the major processes carried out to separate therapeutic protein components from whole blood in the plasma fractionation equipment. Protein components such as prothrombin complex, thrombin, fibrinogen, and others play a major role in managing diseases. These fractionation plasma products have therapeutic efficiencies in treating diseases such as congenital metabolic deficiencies, trauma, immunological disorders, and other life-threatening diseases.

Use of Plasma Therapy in COVID-19 Patients to Boost Market Potential

The outbreak of COVID-19 has urged scientists to experiment with plasma therapy on affected people. According to the New York Times, there were over 70,000 new cases of COVID-19 on 29 March 2021 in the U.S. alone.  In the initial phases of the outbreak, the patients were administered blood plasma for recovery as there was no specific treatment medicine or vaccine against the disease. The U.S. FDA is yet to approve the use of plasma therapy for the treatment of COVID-19. Plasma from the infected individual is studied as an investigational drug product among COVID-19 positive individuals. The promising results shown by plasma therapy in disease management and recovery will spur lucrative growth opportunities for the plasma fractionation industry.


Request a Free sample to learn more about this report.

Shift Towards Advanced Treatment Options to Boost Market Growth

The rising demand for plasma products globally has enabled manufacturers to dedicate manufacturing units to produce plasma proteins. This was significantly witnessed in countries like China. China is among the largest producers and consumers of plasma-derived products. According to the journal Annals of Blood, nearly 7 million liters of plasma gets collected in China per year. According to the data published in the National Institute of Health research paper, 40,000 kg of intravenous immunoglobulin and 500,000 kg of human albumin are produced each year worldwide. Therefore, the increasing focus on developing advanced treatment solutions is expected to favor the growth of the global market of plasma fractionation in the forthcoming years.


Increasing Adoption of Immunoglobulin to Bolster Market Growth

One of the most predominant and crucial factors for the growth of the market is the increasing adoption of immunoglobulin for the management, treatment, and diagnosis of metabolic diseases worldwide. Thus, the high utilization of immunoglobulin will magnify its dominance and improve market prospects. Immunoglobulin is glycoprotein molecules that are derived through plasma and act as antibodies. There has been constant research and development to cognize the efficacy and therapeutic nature of immunoglobulin to treat complex diseases such as Alzheimer’s and other autoimmune disorders. These factors cumulatively are anticipated to drive the plasma fractionation market growth.

Establishment of GLP Compliant Facilities to Augment Market Growth

The growing focus on establishing advanced plasma fractionation plants by key market players is likely to augment the growth of the market. For instance, in February 2019, Kedrion Biopharma announced that the company received FDA approval for establishing a plasma fractionation facility in Melville that would be dedicated to producing plasma proteins. Such facilities are of utmost importance to carry out the process in a sterile micro-organism-free environment. Additionally, in light of the 2019-2020 global pandemic, such facilities will play a crucial role in maintaining the supply-demand cycle of plasma derivatives worldwide. This has, in turn, accelerated the growth of the market


Stringent Regulatory Policies to Restrain Market Growth

As the plasma fractionation products are derived from whole blood, the products are stringently regulated by regulatory bodies. Stringent regulations on the manufacturing facility, source of whole blood, isolation process, among others can restrain the growth of the market. Such rigorous policies could impact the development and manufacturing time of the product. Additionally, the development of vaccines to inhibit the spread of the COVID-19 could also impact the sales of these products in the forthcoming years.


By Product Type Analysis

To know how our report can help streamline your business, Speak to Analyst

Protease Inhibitor Segment to Witness Significant Growth during Forecast Duration

Based on product type, the global market is categorized into albumin, immunoglobulin (intravenous immunoglobulin and subcutaneous immunoglobulin), coagulation factors (Factor IX, Factor VIII, prothrombin complex concentrates, fibrinogen concentrates, and others), protease inhibitors, others. Immunoglobulin dominated the market followed by coagulation factors. The dominant position of immunoglobulins is attributable to the rapid demand in the product owing to its wide range of applications in the treatment of autoimmune disorders.

Due to its efficacy in preventing viral infections, protease inhibitors are projected to witness the highest growth in the coming years. Protease inhibitors are widely used as antiviral agents. Increasing incidences and outbreaks of viral outbreaks are estimated to propel the segment growth over the forecast duration. Also, the increasing demand for coagulation factor concentrates is driving the growth of the product type.

By Application Analysis

Immunology and Neurology to Witness Highest CAGR

Based on the application, the global market is segmented into immunology & neurology, hematology, critical care, pulmonology, and others.

The immunology and neurology segments are projected to grow at a higher growth rate during the forecast period. This is attributed to the extensive use of plasma proteins such as coagulation and immunoglobulin in neurology R&D and treatment procedures. Additionally, immunoglobulin has shown promise in treating complex disease indications such as myasthenia gravis, Alzheimer’s, bleeding disorder among others. Combined with this, there is numerous plasma-based protein under development and clinical trials for neurology and immunology applications.

The prevalence of genetic disorders such as hemophilia is predicted to fuel the demand for coagulation factors in the coming years. The hematology segment has captured a considerable market share in 2020.

By End-user Analysis

Hospitals to Register a Higher CAGR over the Forecast Duration

In terms of end-user, the market is categorized into hospitals & clinics, research laboratories, and others (academic institutes).

The dominant revenue is generated by the hospitals & clinics segment based on market trends. This is attributed to the high need for plasma fractionated products in advanced clinical settings to treat complex diseases. In addition to this, the rising number of in-patients would boost the market growth.


North America Plasma Fractionation Market Size, 2020 (USD Billion)

To get more information on the regional analysis of this market, Request a Free sample

North America stood at USD 12.55 billion in 2020 and is estimated to dominate the global plasma fractionation market during the forecast period. The dominance is attributable to the increasing number of research and development in the field combined with highly developed infrastructure. Favorable government regulations and recent FDA-approved therapies are projected to further augment the growth of the market in the coming years. In light of the COVID-19 pandemic, the U.S. FDA has encouraged the survivors of the disease to actively participate in plasma donations.

Europe, on the other hand, secured the second position in terms of market share. This is due to the rising prevalence of rare disease, and increasing investments in plasma fractionation systems are augmenting the market growth in the region.

High investment in drug discovery and evolving healthcare research infrastructure in countries like India and China are expected to drive the market growth in Asia Pacific.

To know how our report can help streamline your business, Speak to Analyst

Latin America and the Middle East and Africa are estimated to register comparatively slower growth during the forecast period owing to the lesser adoption of products for R&D activities coupled with lack of advanced laboratory infrastructure to carry out product developments.


Product Launch by CSL to Strengthen its Market Position

The market is consolidated with major players such as CSL and Grifols, S.A., among others dominating the market. Higher spending in research and increased focus on manufacturing biologics are major factors that have led CSL to dominate the market. Grifols and CSL together hold around 45% in terms of global market revenue. Other plasma fractionation companies that are in the race to gain a significant share in the market are Baxter, Kedrion S.p.A, and the Shire among others. Continuous efforts in launching advanced products coupled with investments in RD are attributable to the penetration of the companies in the global market.



  • January 2019 – Takeda Pharmaceutical Company Limited completed the acquisition of Shire, one of the leaders in the biopharmaceutical industry in Japan.

  • March 2020 – One of the hospitals in Houston, U.S, became the first healthcare institute to test plasma therapy in a COVID-19. The treatment method is called convalescent serum therapy.


An Infographic Representation of Plasma Fractionation Market

To get information on various segments, share your queries with us

The market research report provides a detailed market share analysis and focuses on key aspects such as leading companies, product types, and leading product applications. Besides this, the report offers insights into the market trends, market dynamics, competitive landscape, highlights key industry developments, and the impact of COVID-19. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the advanced market over recent years.

Report Scope & Segmentation



Study Period


Base Year


Estimated Year


Forecast Period


Historical Period



  Value (USD billion)


  Product Type; Application; End User; and Region

By Product Type

  • Immunoglobulin

  • Albumin

  • Coagulation Factors

  • Protease Inhibitors

  • Others

By Application


  • Immunology & Neurology

  • Hematology

  • Critical Care

  • Pulmonology

  • Others

By End-User

  • Hospitals & Clinics

  • Clinical Research Laboratories

  • Others

By Region

  • North America (By Product Type, By Application, By End User, and By Country)

    • U.S. (By Product Type)

    • Canada (By Product Type)

  • Europe (By Product Type, By Application, By End User, and By Country)

    • U.K. (By Product Type)

    • Germany (By Product Type)

    • France (By Product Type)

    • Italy (By Product Type)

    • Spain (By Product Type)

    • Rest of Europe (By Product Type)

  • Asia Pacific (By product Type, By Application, By End User, and By Country)

    • China (By Product Type)

    • Japan (By Product Type)

    • India (By Product Type)

    • Australia (By Product Type)

    • Southeast Asia (By Product Type)

    • Rest of Asia Pacific (By Product Type)

  • Latin America (By Product Type, By Application, By End Use, and By Country)

    • Brazil (By Product Type)

    • Mexico (By Product Type)

    • Rest of Latin America (By Product Type)

  • Middle East & Africa (By Product Type, By Application, By End User, and By Country)

    • GCC (By Product Type)

    • South Africa (By Product Type)

    • Rest of Middle East & Africa (By Product Type)

Frequently Asked Questions

Fortune Business Insights says that the global market size was USD 29.10 billion in 2020 and is projected to reach USD 51.83 billion by 2028.

In 2020, North America stood at USD 12.55 billion.

Registering a CAGR of 6.9%, the market will exhibit steady growth during the forecast period (2021-2028).

The immunoglobulin segment is expected to be the leading segment in this market during the forecast period.

The increasing adoption of immunoglobulin is the major factor driving the growth of the market.

CSL and Grifols, S.A are the major players in the global market.

North America dominated the market share in 2020.

The introduction of advanced therapies by market players is expected to drive the adoption in the global market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
Plasma Fractionation Market Size, Share and Global Industry Trend Forecast till 2026
  • Oct, 2021
  • 2020
  • 2017-2019
  • 140


  • $4850
    Buy Now

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.